We have located links that may give you full text access.
Journal Article
Meta-Analysis
Review
Diagnostic performance of contrast-enhanced ultrasound for pancreatic neoplasms: A systematic review and meta-analysis.
Digestive and Liver Disease 2018 Februrary
BACKGROUND: Early diagnosis of pancreatic cancer is essential to optimize treatment strategies.
OBJECTIVES: To evaluate the diagnostic performance of contrast-enhanced ultrasound for benign and malignant pancreatic neoplasms.
DATA SOURCES: Pubmed, Embase, Web of Science, and Cochrane Library databases.
STUDY ELIGIBILITY CRITERIA: Retrospective or prospective studies.
PARTICIPANTS: Patients with a confirmed diagnosis of benign and malignant pancreatic neoplasms.
INTERVENTION: Contrast-enhanced ultrasound.
STUDY APPRAISAL AND SYNTHESIS: Pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic risk ratio, and corresponding 95% confidence intervals; summary receiver operating characteristic (SROC) curve; a Fagan nomogram.
RESULTS: Ten studies involving 641 patients were included. Pooled sensitivity, specificity, and positive and negative predictive values were 91% (95% CI: 87%, 93%), 87% (95% CI: 78%, 93%), 7.2 (95% CI: 4.3, 12.3), and 0.11 (95% CI: 0.08, 0.15), respectively; and the odds ratio for diagnosis was 67 (95% CI: 34, 113). Contrast-enhanced ultrasound had good diagnostic ability and accuracy. Pre- and post-test probability of disease was 50% and 88%, respectively, when the positive likelihood ratio was 7.
CONCLUSION: Contrast-enhanced ultrasound can be used for qualitative diagnosis of benign and malignant pancreatic neoplasms.
IMPLICATIONS OF KEY FINDINGS: CEUS should be considered as an important imaging tool for the characterization of pancreatic tumors.
SYSTEMATIC REVIEW REGISTRATION NUMBER: CRD42017070434 (PROSPERO).
OBJECTIVES: To evaluate the diagnostic performance of contrast-enhanced ultrasound for benign and malignant pancreatic neoplasms.
DATA SOURCES: Pubmed, Embase, Web of Science, and Cochrane Library databases.
STUDY ELIGIBILITY CRITERIA: Retrospective or prospective studies.
PARTICIPANTS: Patients with a confirmed diagnosis of benign and malignant pancreatic neoplasms.
INTERVENTION: Contrast-enhanced ultrasound.
STUDY APPRAISAL AND SYNTHESIS: Pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic risk ratio, and corresponding 95% confidence intervals; summary receiver operating characteristic (SROC) curve; a Fagan nomogram.
RESULTS: Ten studies involving 641 patients were included. Pooled sensitivity, specificity, and positive and negative predictive values were 91% (95% CI: 87%, 93%), 87% (95% CI: 78%, 93%), 7.2 (95% CI: 4.3, 12.3), and 0.11 (95% CI: 0.08, 0.15), respectively; and the odds ratio for diagnosis was 67 (95% CI: 34, 113). Contrast-enhanced ultrasound had good diagnostic ability and accuracy. Pre- and post-test probability of disease was 50% and 88%, respectively, when the positive likelihood ratio was 7.
CONCLUSION: Contrast-enhanced ultrasound can be used for qualitative diagnosis of benign and malignant pancreatic neoplasms.
IMPLICATIONS OF KEY FINDINGS: CEUS should be considered as an important imaging tool for the characterization of pancreatic tumors.
SYSTEMATIC REVIEW REGISTRATION NUMBER: CRD42017070434 (PROSPERO).
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app